Author: Catherine Gilliam

Tranexamic Acid Treatment in Trauma Patients with Varying Degrees of Injury
June 30, 2022 Uncategorized Catherine Gilliam

Researchers from the UK and Switzerland have conducted a meta-analysis of the effect of TXA treatment on over 32,000 trauma patients. Their aim was to discover whether survival differs between severely and non-severely injured patients.

Alternative routes to intravenous tranexamic acid for postpartum haemorrhage
June 28, 2022 Uncategorized Catherine Gilliam

Recent research highlights ongoing trials assessing alternatives to intravenous TXA administration. Read the full article here

Injured Women Half as Likely as Men to Receive Tranexamic Acid
May 20, 2022 Uncategorized Catherine Gilliam

New research has found that female trauma patients are half as likely as men to receive tranexamic acid – even though the treatment is equally effective regardless of sex. This highlights the urgent need to improve equity in trauma care. Read the full article here.

Cost-effectiveness of TXA for older adults experiencing mild traumatic brain injury
May 6, 2022 Uncategorized Catherine Gilliam

Mild traumatic brain injury in older adults is a huge problem in the UK. Finding out if tranexamic acid improves outcomes is well worth the cost according to recent economic modelling. The CRASH-4 trial will answer this important question. Read the full article here.

June 30, 2021 Uncategorized Catherine Gilliam

This documentary ‘Her Life Matters’ asks why each year, world-wide tens of thousands of mothers bleed to death needlessly – lives that could be saved by a single injection of an inexpensive generic drug called tranexamic acid. Tranexamic acid was invented sixty years ago to stop mothers from bleeding to death after childbirth.   The Woman trial showed that timely treatment